The most recent WHO guidelines for antiretroviral therapy in adolescents and adults recommend the initiation of HAART between 2 and 8 weeks subsequent to the initiation of TB therapy for severely immunosuppressed coinfected individuals, as defined by a CD4 count <200 mm3 [62]. The gene discussed is CD4; the disease is tuberculosis.